Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Yongping Liu, Jun Meng & Guichan Wang. (2018) Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Design, Development and Therapy 12, pages 3013-3019.
Read now
Read now
Articles from other publishers (14)
Paul Henderson. (2022)
Editorial: earning potential in paediatric‐onset
IBD
—a complex interplay
. Alimentary Pharmacology & Therapeutics 56:6, pages 1084-1085.
Crossref
Crossref
Coren A. Milbury, James Creeden, Wai-Ki Yip, David L. Smith, Varun Pattani, Kristi Maxwell, Bethany Sawchyn, Ole Gjoerup, Wei Meng, Joel Skoletsky, Alvin D. Concepcion, Yanhua Tang, Xiaobo Bai, Ninad Dewal, Pei Ma, Shannon T. Bailey, James Thornton, Dean C. Pavlick, Garrett M. Frampton, Daniel Lieber, Jared White, Christine Burns & Christine Vietz. (2022) Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. PLOS ONE 17:3, pages e0264138.
Crossref
Crossref
Alejandro Mateos-Pujante, María Consuelo Jiménez & Inmaculada Andreu. (2022) Evaluation of phototoxicity induced by the anticancer drug rucaparib. Scientific Reports 12:1.
Crossref
Crossref
Luting Liu & Wanchun Xiong. (2021) Effect of molecular targeted agents in chemotherapy for treating platinum-resistant recurrent ovarian cancer. Medicine 100:32, pages e26849.
Crossref
Crossref
Ye Han, Xiaopeng Yu, Shuqiang Li, Ye Tian & Caigang Liu. (2020) New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer. Frontiers in Oncology 10.
Crossref
Crossref
Kianoush Kashani, Mitchell H. Rosner & Marlies Ostermann. (2020) Creatinine: From physiology to clinical application. European Journal of Internal Medicine 72, pages 9-14.
Crossref
Crossref
Kristin G. Anderson, Valentin Voillet, Breanna M. Bates, Edison Y. Chiu, Madison G. Burnett, Nicolas M. Garcia, Shannon K. Oda, Christopher B. Morse, Ingunn M. Stromnes, Charles W. Drescher, Raphael Gottardo & Philip D. Greenberg. (2019) Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunology Research 7:9, pages 1412-1425.
Crossref
Crossref
Reena Beggs & Eddy S. Yang. 2019. DNA Repair. DNA Repair
135
155
.
Brittany Haynes, Junko Murai & Jung-Min Lee. (2018) Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treatment Reviews 71, pages 1-7.
Crossref
Crossref
Xiao Li, Yuchan Mao, Qiwen Wu, Yuanyuan Liu, Qianqian Wu & Binghuan Wen. (2018) WITHDRAWN: Addition of targeted agents to chemotherapy for persistent or recurrent ovarian cancer: a meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology.
Crossref
Crossref
Charles A. KunosJacek Capala. (2018) National Cancer Institute Programmatic Collaboration for Investigational Radiopharmaceuticals. American Society of Clinical Oncology Educational Book:38, pages 488-494.
Crossref
Crossref
Angela Musella, Erlisa Bardhi, Claudia Marchetti, Laura Vertechy, Giusy Santangelo, Carolina Sassu, Federica Tomao, Francesco Rech, Renzo D'Amelio, Marco Monti, Innocenza Palaia, Ludovico Muzii & Pierluigi Benedetti Panici. (2018) Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treatment Reviews 66, pages 7-14.
Crossref
Crossref
Ettore Capoluongo, Giovanni Scambia & Jean-Marc Nabholtz. (2018)
Main implications related to the switch to
BRCA
1/2 tumor testing in ovarian cancer patients: a proposal of a consensus
. Oncotarget 9:28, pages 19463-19468.
Crossref
Crossref
Ilsa T. Kirby & Michael S. Cohen. 2019. Activity-Based Protein Profiling. Activity-Based Protein Profiling
211
231
.